Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain

SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiners, Nina, Schnurra, Carolin, Trawinski, Henning, Kannenberg, Judith, Hermsdorf, Thomas, Aebischer, Andrea, Schöneberg, Torsten, Reiche, Sven, Jassoy, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175097/
https://www.ncbi.nlm.nih.gov/pubmed/34085159
http://dx.doi.org/10.1007/s10096-021-04284-5
Descripción
Sumario:SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding domain (RBD), or both proteins. The AUROCs were 0.958 (NP), 0.991 (RBD), and 0.992 (NP/RBD). The RBD- and NP/RBD-based ELISAs showed better performance than the NP-based assay. Simultaneous testing for antibodies against NP and RBD increased the number of true and false positives. If maximum diagnostic sensitivity is required, the NP/RBD-based ELISA is preferable. Otherwise, the RBD-based ELISA is sufficient. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-021-04284-5.

Ejemplares similares